Trial Profile

A Phase 2 Basket Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination With Pembrolizumab in Patients With Advanced Solid Cancers

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 18 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Talabostat (Primary)
Indications Advanced breast cancer; Anaplastic astrocytoma; Basal cell cancer; Carcinoma; Colorectal cancer; Endometrial cancer; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Prostate cancer; Sarcoma; Solid tumours; Squamous cell cancer; Uterine cancer; Uveal melanoma
Focus Adverse reactions; Therapeutic Use
Acronyms Basket study

Most Recent Events

21 Mar 2025 Status changed from active, no longer recruiting to discontinued.
13 Feb 2025 Planned End Date changed from 30 Apr 2025 to 30 Dec 2025.
13 Feb 2025 Planned primary completion date changed from 30 Apr 2025 to 30 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com